Strategic Wealth Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Strategic Wealth Partners’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-3	Closed	–	–	828
2018 Q4	$0	Buy	+3	New	+$355	﹤0.01%	724

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Strategic Wealth Partners's ALXN Position: Q1 2019 in Review

Strategic Wealth Partners sold out of Alexion Pharmaceuticals (ALXN) in Q1 2019, closing a stake of 3 shares.

Strategic Wealth Partners first reported a position in ALXN in Q4 2018 and held it in 1 quarter. The position peaked at $0 in Q4 2018. 611 funds tracked by Wall St. Rank hold ALXN as of Q1 2019.

Strategic Wealth Partners reported no remaining Alexion Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Strategic Wealth Partners sold 3 Alexion Pharmaceuticals shares in Q1 2019.
Strategic Wealth Partners first reported a position in Alexion Pharmaceuticals in Q4 2018 and held it in 1 quarter.
Strategic Wealth Partners's Alexion Pharmaceuticals position peaked at $0 in Q4 2018.
611 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2019.

Based on Strategic Wealth Partners's 13F filing for Q1 2019, filed 14 May 2019.